| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:15 | Dividendenbekanntmachungen (15.04.2026) | 2.885 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,63 USD 0,5342 EUR ABBOTT LABORATORIES CDR CA0028221046 0,1109 CAD 0,0683 EUR ABBVIE INC US00287Y1091 1... ► Artikel lesen | |
| 06:54 | Aktien unter Druck, aber mit deutlichem Potenzial - dynaCERT Inc., Eli Lilly, K+S, Novo Nordisk | 970 | Der Finanzinvestor | Am Wochenende scheiterten die Verhandlungen zur Beendigung des Krieges zwischen den USA und dem Iran, doch schon Ende dieser Woche soll es bereits eine nächste Verhandlungsrunde geben. Das machte sich... ► Artikel lesen | |
| 09:06 | JEFFERIES stuft NOVO NORDISK auf 'Hold' | 698 | dpa-AFX-Analyser | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Novo Nordisk auf "Hold" mit einem Kursziel von 270 dänischen Kronen belassen. Die Nachfragen der US-Zulassungsbehörde FDA... ► Artikel lesen | |
| 13:42 | Tilray Brands, Inc.: Tilray Brands Accelerates Next Phase of Global Growth and Market Leadership | 526 | GlobeNewswire (Europe) | NEW YORK and LEAMINGTON, Ontario, April 15, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc.?("Tilray", "our", "we" or the "Company") (NASDAQ: TLRY; TSX: TLRY), a global lifestyle and consumer packaged... ► Artikel lesen | |
| Di | Avant Brands Inc.: Avant Brands Reports Q1 2026 Results Highlighted by 37% Growth in Recreational Revenue | 497 | ACCESS Newswire | KELOWNA, BC / ACCESS Newswire / April 14, 2026 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU)("Avant" or the "Company"), a leading producer of innovative and award-winning cannabis products, today... ► Artikel lesen | |
| 14:10 | Teva Pharmaceutical Industries Ltd: Teva Launches Home Ground Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners | 490 | GlobeNewswire (Europe) | For people living with schizophrenia who may find daily disease management overwhelming due to fragmented support and resources, Home Ground Schizophrenia Community is a centralized destination that... ► Artikel lesen | |
| 13:06 | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications | 446 | GlobeNewswire (Europe) | Dr. Dennis K. McBride, PhD (CAPT, Medical Service Corps, US Navy, Ret., Distinguished Research Fellow, National Defense University, and former senior executive, Office Secretary of Defense) to serve... ► Artikel lesen | |
| 15:04 | Wayfinder Biosciences, Inc.: Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase | 441 | PR Newswire | SEATTLE, April 15, 2026 /PRNewswire/ -- Wayfinder Biosciences, a biotechnology company using small molecules to target undruggable proteins at the RNA level, today... ► Artikel lesen | |
| 07:14 | Cosmo Pharmaceuticals N.V.: Phase III 12-Month Data for Clascoterone 5% Topical Solution Confirm Positive Safety for Chronic Use and Continued Hair Growth, both of which are Statistically Significant | 417 | Newsfile | Ad hoc announcement pursuant to Art. 53 LR Long-term safety profile comparable to vehicle supports suitability for chronic use in a lifelong condition. Patients who remained on continuous... ► Artikel lesen | |
| 14:10 | Boehringer Ingelheim Limited: Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3-targeting T-Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | 391 | GlobeNewswire (Europe) | Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3-targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).
Phase... ► Artikel lesen | |
| 15:53 | Aurora & Co. vor Höllenritt: Tilray schon durch, aber Berichtssaison könnte Cannabis-Aktien beben lassen | 383 | wallstreetONLINE | © Foto: adobe.stock.comDie Quartalsberichtssaison läuft an. Noch plätschert sie vergleichsweise gemächlich dahin. Zunächst stehen die US-Banken im Fokus. Doch in wenigen Tagen wird es auch im Cannabis-Sektor... ► Artikel lesen | |
| 15:26 | Cosmos Health Inc.: Cosmos Health Reports Full Year 2025 Results: Revenue Hits All-Time Record of $65.3M, Up 20%; Gross Profit Surges 83% to $7.9M; Gross Margin Expands 418 Basis Points; Adjusted EPS Improves 82%; Cash Position Up 10x to $3.5M; Record Gro | 379 | ACCESS Newswire | Scaled contract manufacturing division, securing long-term agreements for over 12 million unitsExpanded Sky Premium Life portfolio by 60 SKUs and accelerated global expansion, securing purchase orders... ► Artikel lesen | |
| 17:09 | Merck & Co. (MRK): Die Bullen lauern an der 20-Tagelinie! | 346 | ratgeberGELD.at | Konsolidierung auf hohem Niveau! Rückblick Die Aktie von Merck befindet sich in einer Korrekturphase innerhalb eines starken Aufwärtstrends. Der Markt "atmet durch", nachdem die Kurse schnell gestiegen... ► Artikel lesen | |
| 07:03 | Sandoz Group AG: Sandoz signs landmark agreement with Rwandan government to ensure stable provision of critical medicines across selected African markets | 340 | EQS Group (EN) | Sandoz Group AG
/ Key word(s): Agreement
Sandoz signs landmark agreement with Rwandan government to ensure stable provision of critical medicines across selected African markets... ► Artikel lesen | |
| 14:06 | Reviva Pharmaceuticals: Reviva Announces Letter to Shareholders | 318 | GlobeNewswire (Europe) | CUPERTINO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| PERRIGO | 9,670 | 0,98 | +10,13 % | 0,29 | 02.03.2026 | |
| SANOFI | 81,13 | 3,92 | +4,83 % | 4,12 | 05.05.2026 | |
| NOVO NORDISK | 34,485 | 1,57 | +4,55 % | 7,95 | 27.03.2026 | |
| SINOPHARM | 2,229 | 0,08 | +3,59 % | 0,79 | 23.06.2026 | |
| CHUGAI PHARMACEUTICAL | 45,830 | 1,46 | +3,19 % | 66,00 | 29.06.2026 | |
| NOVARTIS | 129,18 | 4,11 | +3,18 % | 3,70 | 10.03.2026 | |
| GSK | 24,490 | 0,76 | +3,10 % | 0,18 | 19.02.2026 | |
| ROCHE HOLDING | 356,40 | 10,85 | +3,04 % | 9,80 | 12.03.2026 | |
| CSPC PHARMA | 1,044 | 0,03 | +2,87 % | 0,15 | 24.06.2026 | |
| KYOWA KIRIN | 13,300 | 0,33 | +2,48 % | 35,00 | 29.06.2026 |